{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T09:13:45Z","timestamp":1792919625277,"version":"4.5.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The cornerstone of life-saving therapy in immune-mediated thrombotic thrombocytopenic purpura (iTTP) has been plasma exchange (PEX) combined with immunomodulatory strategies. Caplacizumab, a novel anti\u2013von Willebrand factor nanobody trialed in 2 multicenter randomized controlled trials (RCTs) leading to European Union and US Food and Drug Administration approval, has been available in the United Kingdom (UK) through a patient access scheme. Data were collected retrospectively from 2018 to 2020 for 85 patients (4 children) receiving caplacizumab from 22 UK hospitals. Patient characteristics and outcomes in the real-world clinical setting were compared with caplacizumab trial end points and historical outcomes in the precaplacizumab era. Eighty-four of 85 patients received steroid and rituximab alongside PEX; 26% required intubation. Median time to platelet count normalization (3 days), duration of PEX (7 days), and hospital stay (12 days) were comparable with RCT data. Median duration of PEX and time from PEX initiation to platelet count normalization were favorable compared with historical outcomes (P &amp;lt; .05). Thrombotic thrombocytopenic purpura (TTP) recurred in 5 of 85 patients; all had persistent ADAMTS13 activity &amp;lt; 5 IU\/dL. Of 31 adverse events in 26 patients, 17 of 31 (55%) were bleeding episodes, and 5 of 31 (16%) were thrombotic events (2 unrelated to caplacizumab); mortality was 6% (5\/85), with no deaths attributed to caplacizumab. In 4 of 5 deaths, caplacizumab was introduced &amp;gt;48 hours after PEX initiation (3-21 days). This real-world evidence represents the first and largest series of TTP patients, including pediatric patients, receiving caplacizumab outside of clinical trials. Representative of true clinical practice, the findings provide valuable information for clinicians treating TTP globally.<\/jats:p>","DOI":"10.1182\/blood.2020007599","type":"journal-article","created":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T21:57:45Z","timestamp":1604527065000},"page":"1731-1740","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":153,"title":["Real-world experience with caplacizumab in the management of acute TTP"],"prefix":"10.1182","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3049-2395","authenticated-orcid":false,"given":"Tina","family":"Dutt","sequence":"first","affiliation":[{"name":"Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1190-7244","authenticated-orcid":false,"given":"Rebecca J.","family":"Shaw","sequence":"additional","affiliation":[{"name":"Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Stubbs","sequence":"additional","affiliation":[{"name":"University College London Hospitals NHS Foundation Trust, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yong","sequence":"additional","affiliation":[{"name":"Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Bailiff","sequence":"additional","affiliation":[{"name":"University Hospitals Coventry and Warwickshire NHS Foundation Trust, Coventry, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Cranfield","sequence":"additional","affiliation":[{"name":"Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2245-1227","authenticated-orcid":false,"given":"Maeve P.","family":"Crowley","sequence":"additional","affiliation":[{"name":"Cork University Hospital, Cork, Ireland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Desborough","sequence":"additional","affiliation":[{"name":"Guys and St. Thomas NHS Foundation Trust, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6631-9749","authenticated-orcid":false,"given":"Toby A.","family":"Eyre","sequence":"additional","affiliation":[{"name":"Oxford University Hospital NHS Foundation Trust, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Gooding","sequence":"additional","affiliation":[{"name":"University Hospitals of Leicester NHS Trust, Leicester, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2626-0647","authenticated-orcid":false,"given":"John","family":"Grainger","sequence":"additional","affiliation":[{"name":"Manchester University NHS Foundation Trust, Manchester, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hanley","sequence":"additional","affiliation":[{"name":"The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Haughton","sequence":"additional","affiliation":[{"name":"The Mid Yorkshire Hospitals NHS Trust, Wakefield, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joannes","family":"Hermans","sequence":"additional","affiliation":[{"name":"Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0627-4358","authenticated-orcid":false,"given":"Quentin","family":"Hill","sequence":"additional","affiliation":[{"name":"The Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Humphrey","sequence":"additional","affiliation":[{"name":"University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Lowe","sequence":"additional","affiliation":[{"name":"University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamish","family":"Lyall","sequence":"additional","affiliation":[{"name":"Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0951-8079","authenticated-orcid":false,"given":"Muhammad","family":"Mohsin","sequence":"additional","affiliation":[{"name":"Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip L. R.","family":"Nicolson","sequence":"additional","affiliation":[{"name":"University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Priddee","sequence":"additional","affiliation":[{"name":"NHS Lothian, Edinburgh, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2681-5860","authenticated-orcid":false,"given":"Alexandros","family":"Rampotas","sequence":"additional","affiliation":[{"name":"Oxford University Hospital NHS Foundation Trust, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Rayment","sequence":"additional","affiliation":[{"name":"University Hospital of Wales, Cardiff, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Rhodes","sequence":"additional","affiliation":[{"name":"NHS Greater Glasgow and Clyde, Glasgow, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Taylor","sequence":"additional","affiliation":[{"name":"Great Ormond Street Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Thomas","sequence":"additional","affiliation":[{"name":"Cambridge University Hospital NHS Foundation Trust, Cambridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1059-2906","authenticated-orcid":false,"given":"Oliver","family":"Tomkins","sequence":"additional","affiliation":[{"name":"University College London Hospitals NHS Foundation Trust, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost J.","family":"Van Veen","sequence":"additional","affiliation":[{"name":"Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Lane","sequence":"additional","affiliation":[{"name":"Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Hock","family":"Toh","sequence":"additional","affiliation":[{"name":"Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Scully","sequence":"additional","affiliation":[{"name":"University College London Hospitals NHS Foundation Trust, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2021040115260762900_B1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2008-02-078170","article-title":"Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura","volume":"112","author":"Sadler","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2021040115260762900_B2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"Scully","year":"2012","journal-title":"Br J Haematol"},{"issue":"6","key":"2021040115260762900_B3","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med"},{"issue":"21","key":"2021040115260762900_B4","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2021040115260762900_B5","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"Kremer Hovinga","year":"2010","journal-title":"Blood"},{"issue":"17","key":"2021040115260762900_B6","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2012-04-420943","article-title":"Evaluation of efficacy and safety of the anti-VWF nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura","volume":"120","author":"Callewaert","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2021040115260762900_B7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"2021040115260762900_B8","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"2021040115260762900_B9","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/bjh.13658","article-title":"Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative","volume":"171","author":"Bendapudi","year":"2015","journal-title":"Br J Haematol"},{"issue":"4","key":"2021040115260762900_B10","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/trf.15721","article-title":"Deaths and complications associated with the management of acute immune thrombotic thrombocytopenic purpura","volume":"60","author":"Colling","year":"2020","journal-title":"Transfusion"},{"issue":"3","key":"2021040115260762900_B11","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1182\/blood-2010-11-317859","article-title":"Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs","volume":"118","author":"Ulrichts","year":"2011","journal-title":"Blood"},{"issue":"7","key":"2021040115260762900_B12","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1111\/jth.13716","article-title":"Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura","volume":"15","author":"Peyvandi","year":"2017","journal-title":"J Thromb Haemost"},{"key":"2021040115260762900_B13","author":"Shin"},{"issue":"3","key":"2021040115260762900_B14","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/jth.12114","article-title":"Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse","volume":"11","author":"Westwood","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2021040115260762900_B15","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3324\/haematol.2019.226423","article-title":"Long-term neuropsychological sequelae, emotional wellbeing and quality of life in patients with acquired thrombotic thrombocytopenic purpura","volume":"105","author":"Riva","year":"2020","journal-title":"Haematologica"},{"key":"2021040115260762900_B16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.thromres.2017.01.003","article-title":"Post-traumatic stress disorder and depression in survivors of thrombotic thrombocytopenic purpura","volume":"151","author":"Chaturvedi","year":"2017","journal-title":"Thromb Res"},{"issue":"5","key":"2021040115260762900_B17","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/trf.14060","article-title":"Depression and cognitive deficits as long-term consequences of thrombotic thrombocytopenic purpura","volume":"57","author":"Falter","year":"2017","journal-title":"Transfusion"},{"issue":"10","key":"2021040115260762900_B18","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/bloodadvances.2017005124","article-title":"Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015","volume":"1","author":"Page","year":"2017","journal-title":"Blood Adv"},{"key":"2021040115260762900_B19","author":"European Medicines Agency"},{"issue":"1","key":"2021040115260762900_B20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/rth2.12160","article-title":"Thrombotic thrombocytopenic purpura: toward targeted therapy and precision medicine","volume":"3","author":"Coppo","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"7","key":"2021040115260762900_B21","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood"},{"issue":"25","key":"2021040115260762900_B22","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1182\/blood-2014-11-551580","article-title":"How I treat refractory thrombotic thrombocytopenic purpura [published correction appears in Blood. 2017;130(4):1684]","volume":"125","author":"Sayani","year":"2015","journal-title":"Blood"},{"key":"2021040115260762900_B23","doi-asserted-by":"crossref","first-page":"1076029618825309","DOI":"10.1177\/1076029618825309","article-title":"Comparison of the long-term remission of rituximab and conventional treatment for acquired thrombotic thrombocytopenic purpura: a systematic review and meta-analysis","volume":"25","author":"Owattanapanich","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"issue":"7","key":"2021040115260762900_B24","doi-asserted-by":"crossref","first-page":"e27737","DOI":"10.1002\/pbc.27737","article-title":"Use of caplacizumab in a child with refractory thrombotic thrombocytopenic purpura","volume":"66","author":"Bhoopalan","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"2021040115260762900_B25","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00467-019-04281-z","article-title":"Caplacizumab for relapsing thrombotic thrombocytopenic purpura","volume":"34","author":"Kaczmarek","year":"2019","journal-title":"Pediatr Nephrol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/13\/1731\/1803885\/bloodbld2020007599.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/13\/1731\/1803885\/bloodbld2020007599.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T11:29:20Z","timestamp":1617276560000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/13\/1731\/474077\/Real-world-experience-with-caplacizumab-in-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":25,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020007599","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,1]]}}}